Does the media refer more to INVA or AMRX?

In the previous week, Amneal Pharmaceuticals had 9 more articles in the media than Innoviva. MarketBeat recorded 12 mentions for Amneal Pharmaceuticals and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.10 beat Amneal Pharmaceuticals' score of 0.30 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer DFTX or INVA?

In the previous week, Definium Therapeutics had 16 more articles in the media than Innoviva. MarketBeat recorded 19 mentions for Definium Therapeutics and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.10 beat Definium Therapeutics' score of 0.65 indicating that Innoviva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 4 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innoviva 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor INVA or EWTX?

In the previous week, Edgewise Therapeutics had 13 more articles in the media than Innoviva. MarketBeat recorded 16 mentions for Edgewise Therapeutics and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.10 beat Edgewise Therapeutics' score of 0.52 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is INVA or MANE more profitable?

Innoviva has a net margin of 81.19% compared to Veradermics' net margin of 0.00%. Innoviva's return on equity of 28.03% beat Veradermics' return on equity. Company Net Margins Return on Equity Return on Assets Innoviva 81.19% 28.03% 20.19% Veradermics N/A N/A N/A

Does the media refer more to INVA or MANE?

In the previous week, Veradermics had 6 more articles in the media than Innoviva. MarketBeat recorded 9 mentions for Veradermics and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.10 beat Veradermics' score of 0.31 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, INVA or INDV?

Innoviva has higher earnings, but lower revenue than Indivior. Innoviva is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $411.33M 3.72 $271.17M $4.10 5.16 Indivior $1.24B 3.65 $210M $2.79 13.75

Is INVA or INDV more profitable?

Innoviva has a net margin of 81.19% compared to Indivior's net margin of 26.65%. Innoviva's return on equity of 28.03% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets Innoviva 81.19% 28.03% 20.19% Indivior 26.65% -283.11% 36.85%

Does the media prefer INVA or INDV?

In the previous week, Innoviva had 1 more articles in the media than Indivior. MarketBeat recorded 3 mentions for Innoviva and 2 mentions for Indivior. Indivior's average media sentiment score of 1.57 beat Innoviva's score of 1.10 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Innoviva (INVA) Competitors

$21.17 -0.31 (-1.44%)

As of 12:51 PM Eastern

Compare

INVA vs. AMRX, DFTX, EWTX, MANE, and INDV

Should you buy Innoviva stock or one of its competitors? Innoviva's main competitors and comparable companies include Amneal Pharmaceuticals (AMRX), Definium Therapeutics (DFTX), Edgewise Therapeutics (EWTX), Veradermics (MANE), and Indivior (INDV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Innoviva compare to Amneal Pharmaceuticals?

Innoviva (NASDAQ:INVA) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Innoviva has a net margin of 81.19% compared to Amneal Pharmaceuticals' net margin of 5.05%. Innoviva's return on equity of 28.03% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	81.19%	28.03%	20.19%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Innoviva has higher earnings, but lower revenue than Amneal Pharmaceuticals. Innoviva is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.72	$271.17M	$4.10	5.16
Amneal Pharmaceuticals	$3.12B	1.84	$72.06M	$0.49	36.67

Innoviva has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

Innoviva presently has a consensus target price of $34.75, suggesting a potential upside of 64.15%. Amneal Pharmaceuticals has a consensus target price of $17.67, suggesting a potential downside of 1.69%. Given Innoviva's higher probable upside, research analysts plainly believe Innoviva is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 2.0% of Innoviva shares are owned by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Amneal Pharmaceuticals had 9 more articles in the media than Innoviva. MarketBeat recorded 12 mentions for Amneal Pharmaceuticals and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.10 beat Amneal Pharmaceuticals' score of 0.30 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Innoviva beats Amneal Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Innoviva compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Innoviva (NASDAQ:INVA) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

27.9% of Definium Therapeutics shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Innoviva shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Innoviva has a net margin of 81.19% compared to Definium Therapeutics' net margin of 0.00%. Innoviva's return on equity of 28.03% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Innoviva	81.19%	28.03%	20.19%

Definium Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market. Comparatively, Innoviva has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

Innoviva has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Innoviva	$411.33M	3.72	$271.17M	$4.10	5.16

In the previous week, Definium Therapeutics had 16 more articles in the media than Innoviva. MarketBeat recorded 19 mentions for Definium Therapeutics and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.10 beat Definium Therapeutics' score of 0.65 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	4 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Definium Therapeutics currently has a consensus target price of $63.00, suggesting a potential upside of 40.53%. Innoviva has a consensus target price of $34.75, suggesting a potential upside of 64.15%. Given Innoviva's higher probable upside, analysts clearly believe Innoviva is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00
Innoviva	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

Summary

Innoviva beats Definium Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Innoviva compare to Edgewise Therapeutics?

Innoviva (NASDAQ:INVA) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

Innoviva has a net margin of 81.19% compared to Edgewise Therapeutics' net margin of 0.00%. Innoviva's return on equity of 28.03% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	81.19%	28.03%	20.19%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

Innoviva has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.72	$271.17M	$4.10	5.16
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

Innoviva has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

Innoviva presently has a consensus price target of $34.75, suggesting a potential upside of 64.15%. Edgewise Therapeutics has a consensus price target of $49.08, suggesting a potential upside of 11.22%. Given Innoviva's higher probable upside, research analysts plainly believe Innoviva is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

In the previous week, Edgewise Therapeutics had 13 more articles in the media than Innoviva. MarketBeat recorded 16 mentions for Edgewise Therapeutics and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.10 beat Edgewise Therapeutics' score of 0.52 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.1% of Innoviva shares are held by institutional investors. 2.0% of Innoviva shares are held by insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Innoviva beats Edgewise Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Innoviva compare to Veradermics?

Innoviva (NASDAQ:INVA) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

Innoviva has a net margin of 81.19% compared to Veradermics' net margin of 0.00%. Innoviva's return on equity of 28.03% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	81.19%	28.03%	20.19%
Veradermics	N/A	N/A	N/A

Innoviva presently has a consensus price target of $34.75, suggesting a potential upside of 64.15%. Veradermics has a consensus price target of $153.00, suggesting a potential upside of 48.17%. Given Innoviva's higher probable upside, research analysts plainly believe Innoviva is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

99.1% of Innoviva shares are held by institutional investors. 2.0% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Innoviva has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.72	$271.17M	$4.10	5.16
Veradermics	N/A	N/A	-$70M	-$1.90	N/A

In the previous week, Veradermics had 6 more articles in the media than Innoviva. MarketBeat recorded 9 mentions for Veradermics and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.10 beat Veradermics' score of 0.31 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Innoviva beats Veradermics on 11 of the 14 factors compared between the two stocks.

How does Innoviva compare to Indivior?

Innoviva (NASDAQ:INVA) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Innoviva has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Indivior has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

In the previous week, Innoviva had 1 more articles in the media than Indivior. MarketBeat recorded 3 mentions for Innoviva and 2 mentions for Indivior. Indivior's average media sentiment score of 1.57 beat Innoviva's score of 1.10 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Innoviva currently has a consensus target price of $34.75, indicating a potential upside of 64.15%. Indivior has a consensus target price of $45.17, indicating a potential upside of 17.71%. Given Innoviva's higher possible upside, equities analysts clearly believe Innoviva is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Innoviva has a net margin of 81.19% compared to Indivior's net margin of 26.65%. Innoviva's return on equity of 28.03% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	81.19%	28.03%	20.19%
Indivior	26.65%	-283.11%	36.85%

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 2.0% of Innoviva shares are owned by company insiders. Comparatively, 0.7% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Innoviva has higher earnings, but lower revenue than Indivior. Innoviva is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.72	$271.17M	$4.10	5.16
Indivior	$1.24B	3.65	$210M	$2.79	13.75

Summary

Innoviva beats Indivior on 9 of the 16 factors compared between the two stocks.

Get Innoviva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INVA vs. The Competition

Export

Metric	Innoviva	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.53B	$12.45B	$7.28B	$12.76B
Dividend Yield	N/A	2.66%	2.55%	10.29%
P/E Ratio	5.16	777.30	268.89	24.06
Price / Sales	3.72	760.07	618.16	97.53
Price / Cash	4.22	96.52	78.23	52.73
Price / Book	1.24	12.02	13.17	6.18
Net Income	$271.17M	$2.81B	$3.46B	$347.71M
7 Day Performance	2.02%	0.77%	1.47%	-0.70%
1 Month Performance	-0.52%	2.22%	4.60%	2.05%
1 Year Performance	6.12%	7.69%	27.68%	20.00%

Innoviva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INVA Innoviva	3.1086 of 5 stars	$21.17 -1.4%	$34.75 +64.1%	+4.7%	$1.53B	$411.33M	5.16	100
AMRX Amneal Pharmaceuticals	3.0433 of 5 stars	$18.15 +5.1%	$17.67 -2.7%	+94.1%	$5.80B	$3.02B	37.04	8,500
DFTX Definium Therapeutics	3.1304 of 5 stars	$42.63 -2.9%	$62.14 +45.8%	+388.0%	$5.73B	N/A	N/A	40	Analyst Forecast Gap Down
EWTX Edgewise Therapeutics	2.1023 of 5 stars	$44.17 +2.3%	$49.08 +11.1%	+236.5%	$4.80B	N/A	N/A	60
MANE Veradermics	2.2136 of 5 stars	$113.18 +2.0%	$153.00 +35.2%	N/A	$4.71B	N/A	N/A	19	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INVA) was last updated on 8/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Innoviva (INVA) Competitors

INVA vs. AMRX, DFTX, EWTX, MANE, and INDV

How does Innoviva compare to Amneal Pharmaceuticals?

Summary

How does Innoviva compare to Definium Therapeutics?

Summary

How does Innoviva compare to Edgewise Therapeutics?

Summary

How does Innoviva compare to Veradermics?

Summary

How does Innoviva compare to Indivior?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVA vs. The Competition

Innoviva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Innoviva (INVA) Competitors

INVA vs. AMRX, DFTX, EWTX, MANE, and INDV

How does Innoviva compare to Amneal Pharmaceuticals?

Is INVA or AMRX more profitable?

Which has better earnings & valuation, INVA or AMRX?

Which has more risk & volatility, INVA or AMRX?

Do analysts rate INVA or AMRX?

Do insiders and institutionals hold more shares of INVA or AMRX?

Does the media refer more to INVA or AMRX?

Summary

How does Innoviva compare to Definium Therapeutics?

Do institutionals and insiders have more ownership in DFTX or INVA?

Is DFTX or INVA more profitable?

Which has more risk and volatility, DFTX or INVA?

Which has preferable valuation and earnings, DFTX or INVA?

Does the media prefer DFTX or INVA?

Do analysts recommend DFTX or INVA?

Summary

How does Innoviva compare to Edgewise Therapeutics?

Is INVA or EWTX more profitable?

Which has better earnings and valuation, INVA or EWTX?

Which has more risk and volatility, INVA or EWTX?

Do analysts prefer INVA or EWTX?

Does the media favor INVA or EWTX?

Do institutionals & insiders have more ownership in INVA or EWTX?

Summary

How does Innoviva compare to Veradermics?

Is INVA or MANE more profitable?

Do analysts rate INVA or MANE?

Do institutionals & insiders hold more shares of INVA or MANE?

Which has stronger valuation & earnings, INVA or MANE?

Does the media refer more to INVA or MANE?

Summary

How does Innoviva compare to Indivior?

Which has more volatility & risk, INVA or INDV?

Does the media prefer INVA or INDV?

Do analysts recommend INVA or INDV?

Is INVA or INDV more profitable?

Do institutionals & insiders have more ownership in INVA or INDV?

Which has preferable earnings and valuation, INVA or INDV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVA vs. The Competition

Innoviva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools